Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...

Eli Lilly (LLY) closed the most recent trading day at $1,027.51, moving +1.8% from the previous trading session. This change outpaced the S&P 500's 1.07% loss on the day. At the same time, the Dow ...

Eli Lilly, United Airlines and Urban Outfitters lead five stocks that are showing strength, near buy points, as AI stocks ...

Chennai, Dec. 13 -- Highlights: ...

These players are well-positioned to potentially gain next year -- and over time.

Bears mauled AI stocks, but the Dow Jones and Russell 2000 hit new highs last week. Tesla and Eli Lilly are in buy zones.

Steel is a cyclical sector, and several catalysts could propel Nucor stock even higher through the cycle. However, there are ...

But even as Ozempic enters India, there is a growing sense globally that Novo may have already lost the obesity drug war to Mounjaro, Eli Lilly’s blockbuster that has become India’s top-selling drug ...

Recent clinical trials of Novo Nordisk’s blockbuster GLP-1 drug semaglutide for Alzheimer’s disease may have failed to show ...

Investing.com -- Moody’s Ratings has affirmed Eli Lilly and Company ’s Aa3 senior unsecured notes ratings and long-term issuer rating while revising the outlook to positive from stable, the rating ...

The dramatic stock slump, which puts Novo Nordisk at a historically cheap valuation, reflects investor concern over future sales growth and competition, particularly from rival Eli Lilly & Co.

Novo Nordisk’s blockbuster diabetes drug, Ozempic, was officially launched in India on December 12. Unlike in the US and ...